PE20230385A1 - Anticuerpos anti-phf-tau y usos de estos - Google Patents

Anticuerpos anti-phf-tau y usos de estos

Info

Publication number
PE20230385A1
PE20230385A1 PE2022002218A PE2022002218A PE20230385A1 PE 20230385 A1 PE20230385 A1 PE 20230385A1 PE 2022002218 A PE2022002218 A PE 2022002218A PE 2022002218 A PE2022002218 A PE 2022002218A PE 20230385 A1 PE20230385 A1 PE 20230385A1
Authority
PE
Peru
Prior art keywords
antibodies
phf
monoclonal antibody
antigen binding
binding fragment
Prior art date
Application number
PE2022002218A
Other languages
English (en)
Inventor
Kolen Kristof Van
Marc Mercken
Rupesh Nanjunda
Sanjaya Singh
Porte Sherry La
Jiinquan Luo
Pharavee Jaiprasart
Sathyadevi Venkataramani
Rajkumar Ganesan
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20230385A1 publication Critical patent/PE20230385A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)

Abstract

Referido a un anticuerpo monoclonal aislado o fragmento de union al antigeno de este que comprende una region variable de cadena pesada que tiene una secuencia de polipeptidos seleccionada de las sec. con nums. de ident.: 71, 45, 51, 57, entre otros, o una region variable de cadena ligera que tiene una secuencia de polipeptidos seleccionada de las sec. con nums. de ident.: 72, 46, 52, 58, entre otros, en donde el anticuerpo monoclonal o fragmento de union al antigeno de este se une especificamente a un filamento helicoidal pareado (PHF)-tau, preferentemente pHF-tau humano. Tambien se refiere a un acido nucleico aislado que codifica el anticuerpo monoclonal o fragmento de union al antigeno. Ademas, se describen acidos nucleicos que codifican los anticuerpos, composiciones que comprenden los anticuerpos, metodos para producir los anticuerpos y usar los anticuerpos para tratar o prevenir afecciones, tales como tauopatias.
PE2022002218A 2020-04-08 2021-04-07 Anticuerpos anti-phf-tau y usos de estos PE20230385A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063007118P 2020-04-08 2020-04-08
US202063026387P 2020-05-18 2020-05-18
PCT/IB2021/052890 WO2021205359A1 (en) 2020-04-08 2021-04-07 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
PE20230385A1 true PE20230385A1 (es) 2023-03-06

Family

ID=78023121

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022002218A PE20230385A1 (es) 2020-04-08 2021-04-07 Anticuerpos anti-phf-tau y usos de estos

Country Status (18)

Country Link
US (1) US20230151083A1 (es)
EP (1) EP4132569A1 (es)
JP (1) JP2023521763A (es)
KR (1) KR20220166308A (es)
CN (1) CN115697393A (es)
AU (1) AU2021251486A1 (es)
BR (1) BR112022020410A2 (es)
CA (1) CA3179914A1 (es)
CL (1) CL2022002766A1 (es)
CO (1) CO2022015737A2 (es)
CR (1) CR20220505A (es)
DO (1) DOP2022000218A (es)
EC (1) ECSP22078815A (es)
IL (1) IL297231A (es)
MX (1) MX2022012628A (es)
PE (1) PE20230385A1 (es)
TW (1) TW202204402A (es)
WO (1) WO2021205359A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
TW202345899A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(三)
TW202346355A (zh) * 2022-03-11 2023-12-01 比利時商健生藥品公司 多特異性抗體及其用途(二)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20180027566A (ko) * 2015-07-06 2018-03-14 유씨비 바이오파마 에스피알엘 타우 결합 항체
JOP20180021A1 (ar) * 2017-03-16 2019-01-30 Janssen Biotech Inc الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها

Also Published As

Publication number Publication date
DOP2022000218A (es) 2023-04-30
JP2023521763A (ja) 2023-05-25
BR112022020410A2 (pt) 2023-01-03
CO2022015737A2 (es) 2023-02-27
WO2021205359A1 (en) 2021-10-14
IL297231A (en) 2022-12-01
KR20220166308A (ko) 2022-12-16
ECSP22078815A (es) 2022-11-30
CR20220505A (es) 2023-05-31
CN115697393A (zh) 2023-02-03
CL2022002766A1 (es) 2023-04-21
EP4132569A1 (en) 2023-02-15
US20230151083A1 (en) 2023-05-18
TW202204402A (zh) 2022-02-01
MX2022012628A (es) 2023-01-11
CA3179914A1 (en) 2021-10-14
AU2021251486A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
PE20230385A1 (es) Anticuerpos anti-phf-tau y usos de estos
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20181044A1 (es) Anticuerpos anti-pd-1 y composiciones
CO2020014575A2 (es) Anticuerpos anti-cd33, anticuerpos biespecíficos anticd33/ anti-cd3 y usos de estos
EA202092933A1 (ru) Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
AR095240A1 (es) ANTICUERPOS ANTI-TGF-b MODIFICADOS POR INGENIERÍA GENÉTICA Y FRAGMENTOS DE UNIÓN A ANTÍGENOS
CL2019002566A1 (es) Anticuerpos anti-phf-tau y usos de estos.
AR080663A1 (es) Proteinas de union especificas y sus usos
AR068767A1 (es) Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
AR109264A1 (es) Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
PE20020801A1 (es) Anticuerpos contra el receptor del factor de crecimiento similar a insulina
DOP2013000111A (es) Anticuerpos neutralizadores anti-ccl20
PE20191079A1 (es) Inmunoglobulinas y usos de estas
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
PE20231078A1 (es) Anticuerpos anti-tigit
PE20220489A1 (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso
PE20211708A1 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anticgrp o anti-cgrp-r
AR124084A1 (es) ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO
UY39699A (es) Anticuerpos anti-tau y usos de estos
PE20231202A1 (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea
AR122417A1 (es) Anticuerpos anti-phf-tau y usos de estos
EA202192508A1 (ru) Способы получения композиций антитела к фно
AR083971A1 (es) Anticuerpos antiproliferacion humanizados homogeneos